AEON Biopharma (AEON) Income from Continuing Operations (2021 - 2026)
AEON Biopharma (AEON) posted Income from Continuing Operations of 37137000.0 for Q4 2025, down 718.36% sequentially from 4538000.0 in Q3 2025, and down 1540.37% YoY from 2578296.0 in Q4 2024.
AEON Biopharma (AEON) Income from Continuing Operations (2021 - 2026) Analysis & Trends
AEON Biopharma has reported Income from Continuing Operations for 5 years, with the latest figure at 37137000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 1540.37% year-over-year to 37137000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 39222000.0 (down 192.28% YoY) and the FY2025 annual result came in at 30985000.0, down 173.77% from the prior year.
- Income from Continuing Operations declined to 37137000.0 in Q4 2025 per AEON's latest filing, from 4538000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 164112000.0 in Q2 2024 and troughed at 297711000.0 in Q3 2023.
- A 5-year average of 19295653.95 and a median of 4538000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 1540.39% in 2022, down 14043.78% in 2022.
- Over 5 years, Income from Continuing Operations stood at 247874.0 in 2021, then slumped by 14043.78% to 34563000.0 in 2022, then sank by 761.36% to 297711000.0 in 2023, then soared by 100.87% to 2578296.0 in 2024, then sank by 1540.37% to 37137000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 37137000.0, 4538000.0, and 6642000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | AEON Biopharma | 10.06 Mn | 6.62 Mn | - | -1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.16 Mn |
| Dec 31, 2025 | -37.14 Mn |
| Sep 30, 2025 | -4.54 Mn |
| Jun 30, 2025 | -6.64 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Dec 31, 2024 | 2.58 Mn |
| Sep 30, 2024 | -6.17 Mn |
| Jun 30, 2024 | 164.11 Mn |
| Mar 31, 2024 | -118.02 Mn |
| Sep 30, 2023 | -297.71 Mn |
| Jun 30, 2023 | -15.47 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -34.56 Mn |
| Sep 30, 2022 | -10.44 Mn |
| Jun 30, 2022 | 1.87 Mn |
| Mar 31, 2022 | 2.77 Mn |
| Dec 31, 2021 | 247,874.00 |
| Sep 30, 2021 | 5.66 Mn |
| Jun 30, 2021 | -4.03 Mn |
| Mar 31, 2021 | -192,544.00 |